CAMBRIDGE, Mass.– Enveric Biosciences (NASDAQ: ENVB), a biotechnology company developing next-generation neuroplastogenic small molecules for psychiatric and neurological disorders, today announced it has relocated its corporate headquarters to Cambridge, Massachusetts.
The move positions Enveric in the heart of the Greater Boston biotech hub, which the company believes will strengthen collaborations, attract top-tier talent, and increase visibility within one of the world’s leading life sciences ecosystems—home to premier academic institutions, biopharma leaders, and a dynamic investor community.
“Relocating our headquarters to Cambridge represents an important step in Enveric’s growth trajectory,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “The Greater Boston biotech hub offers unparalleled access to scientific innovation, industry leadership, and capital markets. These advantages will be beneficial as we prepare to advance our lead molecule, EB-003, into first-in-human clinical trials and pursue our vision of transforming the treatment landscape for patients living with serious neuropsychiatric conditions.”
EB-003, Enveric’s lead development candidate, is designed to deliver the therapeutic benefits of neuroplastogens while minimizing hallucinatory effects. The company recently unveiled EB-003 as the first representative of a novel potential pharmacological class of neuroplastogens, defined by dual engagement of the 5-HT₂A and 5-HT₁B receptors. Supported by encouraging preclinical data, Enveric is advancing EB-003 toward an Investigational New Drug (IND) submission, with first-in-human studies planned for 2026.
